These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 9119152

  • 1. Adventitious agents from animal-derived raw materials--a method of risk assessment.
    Foster LG.
    Dev Biol Stand; 1996; 88():283-90. PubMed ID: 9119152
    [Abstract] [Full Text] [Related]

  • 2. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW, Golker CF, Stadler P.
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [Abstract] [Full Text] [Related]

  • 3. Adventitious agents from animal-derived raw materials and production systems.
    Hellman KB, Honstead JP, Vincent CK.
    Dev Biol Stand; 1996; 88():231-4. PubMed ID: 9119142
    [No Abstract] [Full Text] [Related]

  • 4. Risk reduction in biotherapeutic products.
    Ill CR, Dehghani H.
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [Abstract] [Full Text] [Related]

  • 5. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE).
    Rohwer RG.
    Dev Biol Stand; 1996 Mar; 88():247-56. PubMed ID: 9119146
    [Abstract] [Full Text] [Related]

  • 6. Use of substances of animal origin in pharmaceutics and compliance with the TSE-risk guideline -- a market survey.
    Berger CN, Le Donne P, Windemann H.
    Biologicals; 2005 Mar; 33(1):1-7. PubMed ID: 15713551
    [Abstract] [Full Text] [Related]

  • 7. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS.
    Dev Biol Stand; 1996 Mar; 88():9-11. PubMed ID: 9119167
    [Abstract] [Full Text] [Related]

  • 8. Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses.
    Pocchiari M.
    Dev Biol Stand; 1991 Mar; 75():87-95. PubMed ID: 1794633
    [Abstract] [Full Text] [Related]

  • 9. Tracing and control of raw materials sourcing for vaccine manufacturers.
    Faretra Peysson L.
    Biologicals; 2010 May; 38(3):352-3. PubMed ID: 20335052
    [Abstract] [Full Text] [Related]

  • 10. Process scale considerations in evaluation studies and scale-up.
    Walter JK, Werz W, Berthold W.
    Dev Biol Stand; 1996 May; 88():99-108. PubMed ID: 9119169
    [Abstract] [Full Text] [Related]

  • 11. Bovine serum: reducing the variables through the use of donor herds.
    Rolleston WB.
    Dev Biol Stand; 1999 May; 99():79-86. PubMed ID: 10404879
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of anti-viral filters.
    Hughes B, Bradburne A, Sheppard A, Young D.
    Dev Biol Stand; 1996 May; 88():91-8. PubMed ID: 9119168
    [Abstract] [Full Text] [Related]

  • 13. Safety issues of animal products used in serum-free media.
    Merten OW.
    Dev Biol Stand; 1999 May; 99():167-80. PubMed ID: 10404888
    [Abstract] [Full Text] [Related]

  • 14. Relationship between nature and source of risk and process validation.
    Berthold W, Werz W, Walter JK.
    Dev Biol Stand; 1996 May; 88():59-71. PubMed ID: 9119164
    [No Abstract] [Full Text] [Related]

  • 15. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
    Lubiniecki AS, McAllister PR, Smith TM, Shadle PJ.
    Dev Biol Stand; 1996 May; 88():309-15. PubMed ID: 9119154
    [No Abstract] [Full Text] [Related]

  • 16. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C.
    Dev Biol Stand; 1996 May; 88():125-30. PubMed ID: 9119123
    [Abstract] [Full Text] [Related]

  • 17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials.
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [Abstract] [Full Text] [Related]

  • 18. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M, Taffs RE, Scott D, Asher DM, Brorson K.
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [Abstract] [Full Text] [Related]

  • 19. [Viral safety concept: application to blood and blood products].
    Trouvin JH.
    Rev Prat; 2005 Nov 30; 55(18):2033-8. PubMed ID: 16419908
    [Abstract] [Full Text] [Related]

  • 20. The development, benefits and disadvantages of serum-free media.
    Froud SJ.
    Dev Biol Stand; 1999 Nov 30; 99():157-66. PubMed ID: 10404887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.